Diethoxymethylsilane

We are Diethoxymethylsilane CAS:2031-62-1 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:Diethoxymethylsilane
CAS.NO:2031-62-1
Synonyms:Diethoxy(methyl)silane; Silane, diethoxymethyl-; Silane,diethoxymethyl; Methyldiethoxysilane; diethoxymethyl-silan;
Molecular Formula:C5H14O2Si
Molecular Weight:134.24900
 
Physical and Chemical Properties:
Density:0.838;
Boiling point:94-95oC;
Flash point:10oC;
Index of Refraction:1.3760;
 
Specification:
Appearance:Colorless clear liquid
Purity(GC):≥99.0%
 
Packing:170 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:It can be used as an intermediate for other functional organosilanes.

Diethoxymethylsilane


Related News: Our pharma and biotech offering includes registration and commercialization of products through in-licensing and flexible partnerships.5-(Trifluoromethyl)pyridine-2-carboxylic acid This requires enterprises to have high R & D strength and strategic foresight, keep reserves projects, and seize the market after patents expire.3-Fluoro-2-methylbenzaldehyde At the same time, due to the increase in production costs and environmental protection cost pressures in Europe and the United States, as well as the improvement of process technology, production quality, and registration and certification capabilities of China’s bulk drug manufacturers, bulk drug companies have accelerated their transfer to China, and the bulk drug industry in China has produced Scale continues to increase.clorhidrato de etil (3S, 4R) -4-amino-3-metoxipiperidina-1-carboxilato CAS:83863-71-2 The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study.The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study.

Related Products
Product Name
BOC-D-TIC-OH View Details
Tetrahydrocyclopenta[c]pyrrole-1,3(2H,3aH)-dione View Details
4-Amino-3-chlorophenol View Details
4-chlorobenzoyl chloride manufacturer triphenyl(3-phenylmethoxypropyl)phosphanium,bromide manufacturer 3-Amino-5-bromobenzotrifluoride manufacturer 5-Fluoro-2-hydroxypyridine manufacturer 2,3,4-Trifluorobenzonitrile manufacturer